S'abonner

Individualized treatment of preterm premature rupture of membranes to prolong the latency period, reduce the rate of preterm birth, and improve neonatal outcomes - 20/07/22

Doi : 10.1016/j.ajog.2022.02.037 
Stefania Ronzoni, MD, PhD a, , Teresa Cobo, MD, PhD b, Rohan D’Souza, MD, PhD c, d, Elizabeth Asztalos, MD e, f, Susan E. O’Rinn, BA a, Xingshan Cao, PhD g, h, Ana Herranz, MD b, Nir Melamed, MD a, Silvia Ferrero, MD, PhD i, Jon Barrett, MD a, Victoria Aldecoa, MD b, Montse Palacio, MD, PhD b
a Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada 
b Hospital Clínic of Barcelona (BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine), Fetal I+D Fetal Medicine Research Center, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain 
c Departments of Obstetrics and Gynaecology and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada 
d Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada 
e Department of Newborn and Developmental Pediatrics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 
f University of Toronto, Toronto, Ontario, Canada 
g Research Design and Biostatistics, Sunnybrook Research Institute, Toronto, Ontario, Canada 
h University of Toronto, Toronto, Ontario, Canada 
i Hospital Sant Joan de Déu Barcelona (BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine), Barcelona, Spain 

Corresponding author: Stefania Ronzoni, MD, PhD.

Abstract

Background

Preterm premature rupture of membranes complicates approximately 3% of pregnancies. Currently, in the absence of chorioamnionitis or placental abruption, expectant management, including antenatal steroids for lung maturation and prophylactic antibiotic treatment, is recommended. The benefits of individualized management have not been adequately explored.

Objective

This study aimed to compare the impact of 2 different management strategies of preterm premature rupture of membranes in 2 tertiary obstetrical centers on latency of >7 days, latency to birth, chorioamnionitis, funisitis, and short-term adverse maternal and neonatal outcomes.

Study Design

This was a multicenter retrospective study of women with singleton pregnancies with preterm premature rupture of membranes from 23 0/7 to 33 6/7 weeks of gestation between 2014 and 2018 and undelivered within 24 hours after hospital admission managed at Sunnybrook Health Sciences Center, Toronto, Canada (standard management group), and BCNatal (Hospital Clínic of Barcelona and Hospital Sant Joan de Déu Barcelona), Barcelona, Spain (individualized management group), following local protocols. The standard management group received similar management for all patients, which included a standard antibiotic regimen and routine maternal and fetal surveillance, whereas the individualized management group received personalized management on the basis of amniocentesis at hospital admission (if possible), to rule out microbial invasion of the amniotic cavity and targeted treatment. The exclusion criteria were cervical dilatation >2 cm, active labor, contraindications to expectant management (acute chorioamnionitis, placental abruption, or abnormal fetal tracing), and major fetal anomalies. The primary outcome was latency of >7 days, and the secondary outcomes included latency to birth, chorioamnionitis, and short-term adverse maternal and neonatal outcomes. Statistical comparisons between groups were conducted with propensity score weighting.

Results

A total of 513 pregnancies with preterm premature rupture of membranes were included in this study: 324 patients received standard management, and 189 patients received individualized management, wherein amniocentesis was performed in 112 cases (59.3%). After propensity score weighting, patients receiving individualized management had a higher latency of >7 days (76.0% vs 41.6%; P<.001) and latency to birth (18.1±14.7 vs 9.7±9.7 days; P<.001). Although a higher rate of clinical chorioamnionitis was suspected in the individualized management group than the standard group (34.5% vs 22.0%; P<.01), there was no difference between the groups in terms of histologic chorioamnionitis (67.2% vs 73.4%; P=.16), funisitis (57.6% vs 58.1%; P=.92), or composite infectious maternal outcomes (9.1% vs 7.9%; P=.64). Prolonged latency in the individualized management group was associated with a significant reduction of preterm birth at <32 weeks of gestation (72.1% vs 90.5%; P<.001), neonatal intensive care unit admission (75.6% vs 83.0%; P=.046), and neonatal respiratory support at 28 days of life (16.1% vs 26.1%; P<.01) compared with that in the standard management group. Moreover, prolonged latency was not associated with neonatal severe morbidity at discharge (survival without severe morbidity, 80.4% vs 73.5%; P=.09).

Conclusion

Individualized management of preterm premature rupture of membranes may prolong pregnancy and reduce preterm birth at <32 weeks of gestation, the need for neonatal support, and neonatal intensive care unit admissions, without an increase in histologic chorioamnionitis, funisitis, neonatal infection–related morbidity, and short-term adverse maternal and neonatal outcomes.

Le texte complet de cet article est disponible en PDF.

Key words : amniocentesis, antibiotic treatment, clinical chorioamnionitis, funisitis, histologic chorioamnionitis, intra-amniotic infection, maternal sepsis, microbial invasion of the amniotic cavity, neonatal short-term outcomes, personalized treatment


Plan


 The authors report no conflict of interest.
 Cite this article as: Ronzoni S, Cobo T, D’Souza R, et al. Individualized treatment of preterm premature rupture of membranes to prolong the latency period, reduce the rate of preterm birth, and improve neonatal outcomes. Am J Obstet Gynecol 2022;227:296.e1-18.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 227 - N° 2

P. 296.e1-296.e18 - août 2022 Retour au numéro
Article précédent Article précédent
  • Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia
  • Jonathan Lai, Argyro Syngelaki, Kypros H. Nicolaides, Peter von Dadelszen, Laura A. Magee
| Article suivant Article suivant
  • Cerebral biomarkers in neurologic complications of preeclampsia
  • Lina Bergman, Roxanne Hastie, Emma Bokström-Rees, Henrik Zetterberg, Kaj Blennow, Sonja Schell, Henrik Imberg, Eduard Langenegger, Ashley Moodley, Susan Walker, Stephen Tong, Catherine Cluver

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.